Urovant raises $140 million IPO

Urovant Sciences Ltd. (NASDAQ:UROV), the urology subsidiary of Roivant Sciences GmbH (Basel, Switzerland), raised $140 million late Sept. 26 through the sale of 10 million shares at $14 in an IPO underwritten by J.P. Morgan, Jefferies and Cowen. The offering values the company at $420.4 million. Urovant priced the offering at the bottom of its proposed range of $14-$16.

Urovant was off $2.35 (17%) to $11.65 on Sept. 27...